Engrail Therapeutics
PrivateLast Round
Series B
Extension
Aug 8, 2024
Total Funding Raised
$241M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Engrail Therapeutics is a clinical-stage pharmaceutical company that develops precision-targeted therapies for patients with neuropsychiatric and neurodevelopmental disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine, Mental Health
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Engrail Therapeutics Comparables
Compare Engrail Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Autobahn Therapeutics | 79% | |
| Neumora | 77% | |
| Alto Neuroscience | 75% | |
Engrail Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Aug 8, 2024 | ||||
| Series B | Mar 19, 2024 | ||||
| Series A Extension | Aug 3, 2021 | ||||
| Series A | Jun 18, 2020 |
Key People
Founding team and executive leadership
Engrail Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion | Series B |
| abrdn Inc. | Series B |
| F-Prime Capital | Series B |
| Eight Roads Ventures | Series B |
| Ysios Capital | Series B |
| Nan Fung Life Sciences | Series A Extension, Series A |
| Norwest Venture Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 45% MoM.
- Jul 16, 2025
ENX-101 evaluated for antiseizure effects in GAERS model.
Engrail Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Engrail Therapeutics's valuation, stock price, and market status.